Physician profile
Harpreet Tsui
NPI 1861648545
$1,934.06
in general payments reported to CMS, 2019-2025
14 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.86 · 2020: $25.60 · 2021: $1,631 · 2022: $117 · 2023: $13.42 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $1,430.00 | 2021 | |
| Amgen INC. | $123.03 | 2020-2021 | |
| Novo Nordisk INC | $76.92 | 2021-2023 | Wegovy |
| Lilly USA, LLC | $59.41 | 2022-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $40.78 | 2025 | Nucala |
| Otsuka America Pharmaceutical, INC. | $36.19 | 2021-2022 | |
| Abbvie INC. | $35.76 | 2021-2022 | |
| Philips North America LLC | $34.03 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Regeneron Healthcare Solutions, INC. | $24.09 | 2025 | Dupixent |
| Gilead Sciences, INC. | $18.67 | 2021 | |
| Amarin Pharma, INC. | $16.91 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.21 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.20 | 2022 | |
| Boston Scientific Corporation | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harpreet Tsui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.